1 / 20

Chapter 41

Chapter 41. Medications for Dementia. Drug Overview. Cognitive Function Cholinesterase inhibitors donepezil (Aricept) rivastigmine (Excelon) galantamine (Razadyne) NMDA receptor antagonist memantine hydrochloride (Namenda). Drug Overview. Cholinesterase Inhibitors

anthea
Télécharger la présentation

Chapter 41

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chapter 41 Medications for Dementia

  2. Drug Overview • Cognitive Function • Cholinesterase inhibitors • donepezil (Aricept) • rivastigmine (Excelon) • galantamine (Razadyne) • NMDA receptor antagonist • memantine hydrochloride (Namenda)

  3. Drug Overview • Cholinesterase Inhibitors • Management of mild to moderate Alzheimer’s-type dementia • Often initiated by PCPs or after consultation • NMDA Receptor Antagonists • Moderate to severe dementia of Alzheimer’s type • May be given in addition to cholinesterase inhibitors • May be initiated by PCP or after consultation

  4. Mechanism of Action • Cholinesterase Inhibitors • Block enzyme that degrades acetylcholine in the brain resulting in more acetylcholine at the synaptic cleft and enhances cholinergic transmission • Diminishes signs and symptoms of dementia and improves function and slows progression

  5. Mechanism of Action • NMDA Receptor Antagonist • NMDA receptor is linked to learning and memory • Stimulated by glutamic acid • Excessive stimulation leads to excitotoxicity • Blockade of this receptor blocks excitotoxic effects associated with abnormal transmission of glutamate

  6. Treatment Principles • Standardized Guidelines • Screening for dementia: Recommendation and rationale • Practice Parameter • Diagnosis of dementia (an evidence-based review): Report on the Quality Standards Subcommittee of the American Academy of Neurology

  7. Treatment Principles • Cardinal Points of Treatment • Evidence suggests that cholinesterase inhibitors stabilize cognitive and functional ability for approximately 1 year • Tacrine is not widely prescribed because of the need for frequent liver monitoring and qid dosing • Consider donepezil as first line • Potential drug interactions • All metabolized through the CYP 450 enzyme system

  8. Treatment Principles • Cardinal Points of Treatment • Patients with moderate to severe dementia may be started on memantine, which may be given concurrently with donepezil • Identify and treat presence of depression and/or delirium • Avoid medications with sedating or anticholinergic effects • Treat any metabolic disorders, infections, and comorbid illnesses

  9. How to Monitor • Monitoring of Functional Ability and Staging • Folstein Mini-Mental State Exam (MMSE) • Global Deterioration Scale (GDS) • Katz Assessment of ADLs and IADLs • Clinical Evaluation and Family Observation • Laboratory Tests • Liver function tests • CBC • Routine serum chemistry

  10. How to Monitor • Assessment • HR, BP • Signs and symptoms of toxicity

  11. Patient Variables • Geriatrics • Age does not influence metabolism or clearance of cholinesterase inhibitors • Use galantamine with caution in patients with severe renal impairment • Reduce dose of memantine and use with caution in patients with severe renal impairment (CrCl, 5 to 29 ml/min)

  12. Patient Variables • Pediatrics • Efficacy not established • Pregnancy and Lactation • Category C: donepezil • Category B: rivastigmine, galantamine, memantine • No controlled studies in pregnancy • Unknown secretion of drugs into breast milk

  13. Patient Variables • Race and Gender • Plasma concentrations are up to 50% higher in women

  14. Patient Education • Do Not Change Dose Without Consulting Provider • Advise of Initial and Long-term/Delayed Side Effects • Advise of Purpose, Expectations from Treatment, and Time Frame to Note Improvement, Not Cure • Counsel Regarding Behavioral and Environmental Management of Disease

  15. Patient Education • Advise Patient Regarding Long-Term Care, Including In-Home Services, Adult Day Care, Assisted Living Facilities, and Nursing Homes

  16. donepezil (Aricept) • Precautions • May exaggerate succinylcholine-type muscle relaxation in anesthesia • Vagotonic effects on HR may be provoked; use with caution in patients with conduction abnormalities • May increase gastric acid secretion • May cause bladder outflow obstruction • Use with caution in patients with asthma

  17. donepezil (Aricept) • Pharmacokinetics • Absorption: 100% • Peak level: 3 to 4 hours • Half-life: 70 hours • Steady state: 15 days • Metabolization: P450 2D6 and 3A4 • Excretion: Urine (17%)

  18. donepezil (Aricept) • Adverse Effects • Nausea (5% to 19%) • Diarrhea (8% to 15%) • Insomnia (5% to 14%) • Vomiting, fatigue, muscle cramping, anorexia (3% to 8%) • Drug Interactions • CYP 3A4 and 2D6 substrates • No effect on pharmacokinetics of theophylline, cimetidine, warfarin, and digoxin

  19. memantine (Namenda) • Precautions • Seizures, severe renal impairment, genitourinary conditions, concomitant use of other NMDA antagonists • Adverse Effects (8%) • Hypertension, tachycardia, dizziness, headache, back pain, gait abnormalities, arthralgia, confusion, somnolence, hallucinations, others

  20. memantine (Namenda) • Drug Interactions • acetazolamide • cimetidine • dichlorphenamide • hydrochlorothiazide • methazolamide • nicotine • ranitidine • sodium bicarbonate

More Related